A Phase 1 interventional study of Bexagliflozin and Metformin in Type2 Diabetes Mellitus, sponsored by Theracos. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-22.
Sponsored by Theracos · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Bexagliflozin · Diabetes Mellitus, Type 2.
Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 5 that started in 2016, is one of 7 in phase 1, and was the 8th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →1 of the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:
Baylor Research Institute · Sites in United States
Ages 18–84
By country, each count listing its studies:
Bexagliflozin: first FDA approval 2023 (BRENZAVVY). What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 64 across the 15 interventional studies. Of the 12 that completed or were terminated, 12 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 3 most frequent:
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
17 studies in Diabetes Mellitus, Type 2 by Theracos: none open now, none under way, none of them phase 3. Of 16 finished, 16 (100%) have results posted.
Among the 17 studies in Diabetes Mellitus, Type 2 by Theracos, this one is the 10th largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 1, and was the 10th registered.
Theracos’s Diabetes Mellitus, Type 2 studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing bexagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Theracos’s 17 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.
A total of 54 healthy subjects were enrolled and assigned to one of three groups of eighteen. Each group participated in one of three open-label, randomized, three treatment period, crossover studies:
To prevent hypoglycemia, subjects assigned to Group 2 (bexagliflozin/glimepiride DDI) received approximately 300 mL of a solution containing 50 g of glucose with study medication at the time of dosing, as well as approximately 75 mL of a solution containing 12.5 g of glucose every 15 minutes for 4 hours post-dose.
For each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2 (bexagliflozin/glimepiride DDI), subjects were admitted to the clinic on the day before dosing and stayed in the clinic until 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin DDI), subjects stayed in the clinic until 72 h post-dose.
For all Groups, blood samples for PK analysis were collected in each period prior to dosing (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group 3, PK blood samples were also collected at 60 and 72 h post-dose. Plasma concentrations of bexagliflozin and OHAs were determined by validated liquid chromatography tandem mass spectrometry (LC MS/MS) assays.
Urine samples for PD analysis were collected in 12 h intervals. For all Groups, urine samples were collected pre-dose (-12 to 0 h) and post-dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h. For Group 3, additional samples at 48 to 60 h and 60 to 72 h post-dose were collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bexagliflozin
Drug: Metformin
Drug: Bexagliflozin · Drug: Metformin
Drug: Bexagliflozin
Drug: Glimepiride
Drug: Bexagliflozin · Drug: Glimepiride
Drug: Bexagliflozin
Drug: Sitagliptin
Drug: Bexagliflozin · Drug: Sitagliptin
Bexagliflozin tablets, 20 mg
1000 mg metformin
4 mg glimepiride
100 mg sitagliptin
Cmax (Maximum Observed Plasma Concentration)
Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.
Time frame: Up to 72 hours
Tmax (Time of Maximum Observed Plasma Concentration)
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.
Time frame: Up to 72 hours
T1/2 (Apparent Terminal Elimination Half-life)
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.
Time frame: Up to 72 hours
AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.
Time frame: Up to 72 hours
Urinary Glucose Excretion up to 0-72 hr
Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.
Time frame: up to 0-72 hr
| Milestone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|
| Started | 18 | 18 | 18 |
| Completed | 18 | 18 | 18 |
| Not completed | 0 | 0 | 0 |
Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.
| ng/mL | Group 1: Bexagliflozin Alone | Group 1: Metformin Alone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin Alone | Group 2: Glimepiride Alone | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin Alone | Group 3: Sitagliptin Alone | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| Bexagliflozin PK parameters | 124.6 ± 43.7 | — | 135.5 ± 40.0 | 158.6 ± 53.9 | — | 143.7 ± 37.9 | 117.1 ± 34.6 | — | 148.3 ± 22.1 |
| Metformin PK parameters | — | 2067.6 ± 27.2 | 1965.2 ± 33.6 | — | — | — | — | — | — |
| Glimepiride PK parameters | — | — | — | — | 59.9 ± 32.2 | 67.1 ± 29.5 | — | — | — |
| Sitagliptin PK parameters | — | — | — | — | — | — | — | 356.6 ± 22.3 | 351.2 ± 32.9 |
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.
| hours | Group 1: Bexagliflozin Alone | Group 1: Metformin Alone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin Alone | Group 2: Glimepiride Alone | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin Alone | Group 3: Sitagliptin Alone | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| Bexagliflozin PK parameters | 4.0 (1 to 5) | — | 3.0 (1 to 5) | 8.0 (5 to 10) | — | 6.0 (5 to 10) | 3.0 (2 to 5) | — | 4.0 (2 to 5) |
| Metformin PK parameters | — | 2.5 (1 to 3) | 2.0 (1 to 5) | — | 0 (0 to 0) | — | — | — | — |
| Glimepiride PK parameters | — | — | — | — | 5.5 (1 to 10) | 7.0 (1 to 10) | — | — | — |
| Sitagliptin PK parameters | — | — | — | — | — | — | — | 2.5 (1 to 5) | 2.5 (1 to 6) |
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.
| hours | Group 1: Bexagliflozin Alone | Group 1: Metformin Alone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin Alone | Group 2: Glimepiride Alone | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin Alone | Group 3: Sitagliptin Alone | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| Bexagliflozin PK parameters | 10.3 ± 30.4 | — | 7.8 ± 48.6 | 8.0 ± 33.3 | — | 7.8 ± 34.4 | 12.6 ± 48 | — | 13.3 ± 38.2 |
| Metformin PK parameters | — | 9.0 ± 31.8 | 10.2 ± 32.5 | — | — | — | — | — | — |
| Glimepiride PK parameters | — | — | — | — | 7.8 ± 46.8 | 6.6 ± 57.8 | — | — | — |
| Sitagliptin PK parameters | — | — | — | — | — | — | — | 14.3 ± 22.3 | 14.8 ± 24.5 |
Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.
| h*ng/mL | Group 1: Bexagliflozin Alone | Group 1: Metformin Alone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin Alone | Group 2: Glimepiride Alone | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin Alone | Group 3: Sitagliptin Alone | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| Bexagliflozin PK parameters | 1154.4 ± 35.1 | — | 1008.6 ± 40.2 | 1204.9 ± 48.6 | — | 1162.2 ± 47.8 | 1011.8 ± 21.5 | — | 1158.1 ± 21.9 |
| Metformin PK parameters | — | 13351.9 ± 22.5 | 13784.6 ± 26.0 | — | — | — | — | — | — |
| Glimepiride PK parameters | — | — | — | — | 496.1 ± 53.3 | 633.0 ± 38.5 | — | — | — |
| Sitagliptin PK parameters | — | — | — | — | — | — | — | 3579.6 ± 14.7 | 3692.8 ± 16.9 |
Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.
| g | Group 1: Bexagliflozin Alone | Group 1: Metformin Alone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin Alone | Group 2: Glimepiride Alone | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin Alone | Group 3: Sitagliptin Alone | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| 0 - 12 hours | 31.57 ± 8.06 | 0.02 ± 0.01 | 26.26 ± 8.86 | 36.99 ± 14.24 | 1.26 ± 4.37 | 31.02 ± 11.19 | 29.01 ± 6.84 | 0.03 ± 0.01 | 23.94 ± 7.17 |
| 12 - 24 hours | 17.32 ± 11.81 | 0.04 ± 0.03 | 22.57 ± 8.29 | 26.85 ± 9.51 | 0.04 ± 0.05 | 22.59 ± 11.15 | 24.38 ± 7.92 | 0.04 ± 0.05 | 22.85 ± 9.59 |
| 24 - 36 hours | 23.94 ± 9.16 | 0.04 ± 0.04 | 19.50 ± 8.94 | 29.79 ± 10.24 | 0.20 ± 0.42 | 28.46 ± 11.37 | 22.31 ± 8.97 | 0.17 ± 0.56 | 24.15 ± 9.27 |
| 36 - 48 hours | 8.91 ± 4.97 | 0.02 ± 0.01 | 5.53 ± 4.17 | 11.03 ± 7.84 | 0.03 ± 0.01 | 9.34 ± 7.55 | 9.83 ± 6.67 | 0.03 ± 0.01 | 10.17 ± 5.23 |
| 48 - 60 hours | — | — | — | — | — | — | 11.32 ± 8.09 | 0.05 ± 0.07 | 11.50 ± 7.52 |
| 60 - 72 hours | — | — | — | — | — | — | 2.67 ± 3.55 | 0.02 ± 0.01 | 2.70 ± 2.91 |
Collected over Adverse event collection began on the first clinical admission day (Day 0) and continued through D17. The subjects were actively monitored for serious adverse events for at least 14 days after discharge from the study.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Bexagliflozin Alone | 0/18 (0%) | 0/18 (0%) | 3/18 (16.7%) |
| Group 1: Metformin Alone | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| Group 1: Bexagliflozin + Metformin | 0/18 (0%) | 0/18 (0%) | 13/18 (72.2%) |
| Group 2: Bexagliflozin Alone | 0/18 (0%) | 0/18 (0%) | 6/18 (33.3%) |
| Group 2: Glimepiride Alone | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Group 2: Bexagliflozin + Glimepiride | 0/18 (0%) | 0/18 (0%) | 4/18 (22.2%) |
| Group 3: Bexagliflozin Alone | 0/18 (0%) | 0/18 (0%) | 3/18 (16.7%) |
| Group 3: Sitagliptin Alone | 0/18 (0%) | 0/18 (0%) | 1/18 (5.6%) |
| Group 3: Bexagliflozin + Sitagliptin | 0/18 (0%) | 0/18 (0%) | 2/18 (11.1%) |
| Event | Group 1: Bexagliflozin Alone | Group 1: Metformin Alone | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin Alone | Group 2: Glimepiride Alone | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin Alone | Group 3: Sitagliptin Alone | Group 3: Bexagliflozin + Sitagliptin |
|---|---|---|---|---|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 0/18 | 9/18 | 7/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 |
| HeadacheNervous system disorders | 1/18 | 0/18 | 4/18 | 4/18 | 1/18 | 1/18 | 0/18 | 0/18 | 0/18 |
| NauseaGastrointestinal disorders | 0/18 | 3/18 | 2/18 | 2/18 | 1/18 | 3/18 | 0/18 | 0/18 | 0/18 |
| HypoglycemiaMetabolism and nutrition disorders | 2/18 | 0/18 | 0/18 | 1/18 | 1/18 | 0/18 | 3/18 | 0/18 | 0/18 |
| DyspepsiaGastrointestinal disorders | 0/18 | 1/18 | 2/18 | 0/18 | 1/18 | 0/18 | 0/18 | 0/18 | 0/18 |
| VomitingGastrointestinal disorders | 0/18 | 0/18 | 0/18 | 2/18 | 1/18 | 1/18 | 0/18 | 0/18 | 0/18 |
| Abdominal painGastrointestinal disorders | 0/18 | 0/18 | 1/18 | 0/18 | 0/18 | 1/18 | 0/18 | 0/18 | 0/18 |
| Abdominal pain upperGastrointestinal disorders | 0/18 | 1/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 |
| FlatulenceGastrointestinal disorders | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 | 1/18 | 0/18 | 0/18 | 0/18 |
| TendernessGeneral disorders | 0/18 | 0/18 | 1/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 | 0/18 |
| Age, Continuous(years) | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin | Total |
|---|---|---|---|---|
| Mean | 42.2 ± 15.69 | 37.6 ± 8.25 | 43.6 ± 14.52 | 41.1 ± 13.2 |
| Sex: Female, Male(Participants) | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin | Total |
|---|---|---|---|---|
| Female | 6 | 5 | 9 | 20 |
| Male | 12 | 13 | 9 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 18 | 18 | 17 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 5 | 10 | 20 |
| White | 13 | 12 | 8 | 33 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Weight(kg) | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin | Total |
|---|---|---|---|---|
| Mean | 79.0 ± 11.75 | 77.9 ± 12.37 | 79.0 ± 13.21 | 78.6 ± 12.23 |
| Height(cm) | Group 1: Bexagliflozin + Metformin | Group 2: Bexagliflozin + Glimepiride | Group 3: Bexagliflozin + Sitagliptin | Total |
|---|---|---|---|---|
| Mean | 173.3 ± 9.16 | 172.3 ± 6.45 | 170.5 ± 8.37 | 172.0 ± 8.01 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Nov 2016, a primary completion of Mar 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2021, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bexagliflozin · Metformin · Glimepiride · Sitagliptin
Theracos